Jupiter Topco LLC Makes New Investment in Twist Bioscience Corporation $TWST

Jupiter Topco LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 50,539 shares of the company’s stock, valued at approximately $5,200,000. Jupiter Topco LLC owned about 0.08% of Twist Bioscience as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in TWST. Quarry LP acquired a new stake in Twist Bioscience in the 3rd quarter worth about $28,000. Western Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the first quarter worth approximately $31,000. Strs Ohio purchased a new stake in Twist Bioscience in the first quarter valued at approximately $33,000. Strategic Advocates LLC increased its position in Twist Bioscience by 562.7% during the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after purchasing an additional 906 shares during the last quarter. Finally, SBI Securities Co. Ltd. raised its stake in Twist Bioscience by 68.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after purchasing an additional 571 shares during the period.

Insiders Place Their Bets

In other Twist Bioscience news, CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the sale, the chief financial officer owned 110,276 shares in the company, valued at $10,402,335.08. This trade represents a 2.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 41,570 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $151.98, for a total value of $6,317,808.60. Following the sale, the chief executive officer owned 770,729 shares in the company, valued at $117,135,393.42. This represents a 5.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 193,099 shares of company stock valued at $24,026,581 in the last three months. 3.08% of the stock is owned by insiders.

Twist Bioscience Price Performance

TWST opened at $139.00 on Tuesday. The company has a fifty day simple moving average of $108.03 and a 200 day simple moving average of $74.64. The firm has a market cap of $8.72 billion, a price-to-earnings ratio of -62.61 and a beta of 2.14. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $155.44. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period last year, the firm earned $0.33 EPS. Equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TWST. Leerink Partners set a $110.00 price objective on Twist Bioscience in a report on Thursday, July 16th. Piper Sandler boosted their price target on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Guggenheim reiterated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 24th. Finally, Robert W. Baird raised their price target on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $98.30.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.